Tanya Simuni Selected Research

Isradipine (Dynacirc)

1/2022	Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.
10/2021	Novel Approach to Movement Disorder Society-Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models.
1/2021	Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD).
1/2021	Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease.
11/2020	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study.
1/2017	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).
12/2010	Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tanya Simuni Research Topics

Disease

70	Parkinson Disease (Parkinson's Disease) 04/2024 - 04/2002
14	Disease Progression 04/2024 - 11/2011
7	Tremor (Tremors) 04/2024 - 11/2011
6	Movement Disorders (Movement Disorder) 01/2021 - 04/2014
5	Parkinsonian Disorders (Parkinsonism) 10/2022 - 12/2010
4	Cognitive Dysfunction 02/2024 - 01/2017
4	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 11/2011
3	REM Sleep Behavior Disorder 04/2024 - 01/2018
3	Neurodegenerative Diseases (Neurodegenerative Disease) 10/2022 - 01/2017
3	Psychotic Disorders (Schizoaffective Disorder) 10/2019 - 11/2017
2	Dementia (Dementias) 02/2024 - 11/2011
2	Anosmia 01/2023 - 01/2018
2	Atrophy 10/2022 - 01/2017
2	Hypokinesia (Bradykinesia) 01/2021 - 12/2018
2	Neurobehavioral Manifestations 11/2020 - 01/2014
2	Disorders of Excessive Somnolence (Hypersomnia) 01/2020 - 04/2014
2	Hallucinations (Hallucination) 11/2017 - 11/2012
2	Sleepiness 09/2015 - 04/2014
2	Edema (Dropsy) 11/2012 - 12/2010
1	Heart Arrest (Cardiac Arrest) 01/2023
1	Constipation 01/2023
1	Nausea 01/2023
1	Autonomic Nervous System Diseases (Dysautonomia) 10/2022
1	Striatonigral Degeneration 10/2022
1	Cerebellar Ataxia (Dysmetria) 10/2022
1	Cerebellar Diseases (Cerebellar Syndrome) 10/2022
1	Multiple System Atrophy 10/2022
1	Confusion (Bewilderment) 01/2022
1	Panic Disorder (Panic Attack) 01/2022
1	Injection Site Reaction 11/2021
1	Kidney Calculi (Kidney Stone) 01/2021
1	Synucleinopathies 01/2021
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 11/2019
1	Mitochondrial Diseases (Mitochondrial Disease) 12/2017
1	Drug-Induced Dyskinesia (Dyskinesia, Drug Induced) 04/2016
1	Fatigue 01/2016
1	Inflammation (Inflammations) 01/2015

Drug/Important Bio-Agent (IBA)

20	Biomarkers (Surrogate Marker)IBA 04/2024 - 10/2013
7	Isradipine (Dynacirc)FDA LinkGeneric 01/2022 - 12/2010
6	SynucleinsIBA 04/2024 - 10/2013
6	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 01/2021 - 11/2011
5	Glucosylceramidase (Glucocerebrosidase)IBA 01/2023 - 01/2018
5	Levodopa (L Dopa)FDA LinkGeneric 01/2022 - 01/2015
4	alpha-SynucleinIBA 10/2022 - 09/2015
4	Antipsychotic Agents (Antipsychotics)IBA 01/2020 - 11/2017
3	Amyloid (Amyloid Fibrils)IBA 02/2024 - 10/2013
3	Inosine FDA Link 01/2022 - 01/2021
3	Uric Acid (Urate)IBA 01/2022 - 01/2020
3	pimavanserinIBA 10/2019 - 11/2017
2	Monoamine Oxidase (MAO)IBA 04/2024 - 01/2021
2	Monoclonal AntibodiesIBA 04/2024 - 01/2022
2	Dopamine (Intropin)FDA LinkGeneric 06/2023 - 01/2017
2	venglustatIBA 01/2023 - 01/2022
2	1,4-dihydropyridine (dihydropyridine)IBA 01/2021 - 12/2010
2	Hypnotics and Sedatives (Sedatives)IBA 01/2020 - 09/2015
2	Phosphotransferases (Kinase)IBA 01/2020 - 01/2018
2	Leucine (L-Leucine)FDA Link 01/2020 - 01/2018
1	AcidsIBA 01/2023
1	ceramide glucosyltransferaseIBA 01/2023
1	Tyrosine Kinase InhibitorsIBA 01/2023
1	Mitochondrial DNA (mtDNA)IBA 01/2023
1	IronIBA 12/2022
1	AutoantibodiesIBA 10/2022
1	Glucosylceramides (Glucocerebrosides)IBA 01/2022
1	GlycosphingolipidsIBA 01/2022
1	Carbidopa (Lodosyn)FDA LinkGeneric 11/2021
1	Calcium Channels (Calcium Channel)IBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	Neuroprotective AgentsIBA 01/2021
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2021
1	nilotinib FDA Link 01/2021
1	Antidepressive Agents (Antidepressants)IBA 01/2020
1	Cholinergic Antagonists (Anticholinergics)IBA 01/2020
1	Anti-Anxiety Agents (Anxiolytics)IBA 01/2020
1	Dopamine Agonists (Dopamine Agonist)IBA 11/2019
1	amsonic acid (DAS)IBA 11/2019
1	Clozapine (Clozaril)FDA LinkGeneric 12/2018
1	Quetiapine Fumarate (Seroquel)FDA Link 12/2018
1	CalciumIBA 12/2017
1	Medical MarijuanaIBA 01/2017
1	valylvaline (Val-Val)IBA 01/2017
1	Amyloid beta-PeptidesIBA 01/2017
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2017
1	CreatineIBA 02/2015
1	ThiazolidinedionesIBA 02/2015
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2015
1	Interleukin-6 (Interleukin 6)IBA 01/2015
1	Pioglitazone (Actos)FDA Link 01/2015
1	8-Hydroxy-2'-DeoxyguanosineIBA 01/2015

Therapy/Procedure

19	Therapeutics 04/2024 - 04/2002
4	Deep Brain Stimulation 11/2014 - 09/2003
3	Precision Medicine 01/2024 - 01/2020
3	Activities of Daily Living (ADL) 01/2019 - 01/2015
1	Endurance Training 10/2022
1	Drug Therapy (Chemotherapy) 01/2021
1	Physical Therapy Modalities (Physical Therapy Technique) 12/2019
1	Palliative Care (Palliative Therapy) 01/2019
1	Wearable Electronic Devices 01/2019
1	Behavior Control 01/2016
1	Complementary Therapies (Alternative Medicine) 10/2014